Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.

Journal Article

The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

Full Text

Duke Authors

Cited Authors

  • Keane, TE; Rosner, G; Donaldson, JT; Norwood, DL; Poulton, SH; Walther, PJ

Published Date

  • October 1990

Published In

Volume / Issue

  • 144 / 4

Start / End Page

  • 1004 - 1009

PubMed ID

  • 2398547

International Standard Serial Number (ISSN)

  • 0022-5347

Language

  • eng

Conference Location

  • United States